Figure 8. Effect of CHS on the HBP1/Wnt/ TCF7L2 pathway in vivo. DM model was induced by HFD and STZ, and the CHS (120 mg/kg) or positive control rosiglitazone (Ros, 2 mg/kg) was given through intragastric administration one time every day for 30days. FBG (A), FINS (B), GIP (C) and GLP-1 (D) levels in serum were measured using relative kits. (E) Effects of CHS on the expression levels of β-catenin in nuclear. (F) Effects of CHS on the expression levels of apoptosis related proteins (cleaved-caspase 3, bax, bad, cytochrome C) in WT and β-catenin-/- DM mice. (G) Effects of CHS on the expression levels of Wnt3a and HBP1 in DM mice. (H) Effects of CHS on the expression levels of TCF7L2 related proteins (TCF7L2, c-Myc, cyclinD1, Skp2, p53, p21, GLP-1R, GIPR and p27) in WT and β-catenin-/- DM mice. Data are representative of three independent experiments. ##P<0.01 vs. ND mice group, **P<0.01 vs. DM mice group, &&P<0.01 vs. WT DM mice group. (I) Potential mechanism underlying the protective effects of CHS on IHG induced cell injuries in DM mice and pancreas islet cells.